Business Wire

GA-ALVARIA

Share
Alvaria Announces Expansion of Avaya Partnership to Include Alvaria CX Premier Enterprise-scale Omnichannel Compliant Outbound Engagement

Alvaria® is pleased to announce the expansion of our partnership with Avaya, a leading provider of enterprise customer experience solutions, to include the Alvaria CX™ platform in our joint delivery of enterprise-scale high performance solutions for omnichannel-compliant outbound customer engagement.

Alvaria CX will be available in the Avaya One Source store by the end of May. Alvaria will be demonstrating the Alvaria CX high performance omnichannel outbound campaign capabilities to Avaya customers and partners at Avaya ENGAGE in Denver, Colorado, May 13th – 15th. Alvaria CX expands on the Alvaria capabilities available with Avaya by providing additional compliance options and deployment solutions in the customer environment of choice – on-premises, private cloud, public cloud, virtual private cloud (VPC), hybrid.

Omar Javaid, SVP and Chief Product Officer at Avaya, “The pairing of the Alvaria outbound campaign and compliance management tools with Avaya Experience Platform™ enabled call center agents helps address the needs of Avaya's enterprise customers who have sophisticated outbound engagement strategies and the partners who support them.”

“With the addition of Alvaria CX now available as part of the Alvaria portfolio through Avaya and their channel partners, we continue to build our partnership and offer the Avaya global partner network and customers the opportunity to provide premier proactive outreach solutions,” said Jeff Cotten, Alvaria CEO.

Alvaria is proud to be a sponsor of Avaya ENGAGE 2024. Schedule a time to meet with us or stop by Developer Marketplace Booth #530.

About Alvaria

Alvaria makes technology that powers better connections with your team and customers. Proudly celebrating over 50 years in business, Alvaria was created through the merger of two influential contact center technology companies—Aspect Software and Noble Systems. Our foundation is built on delivering sophisticated, feature-rich, and intelligently designed workforce management and contact center infrastructure solutions tailored for large global enterprises and organizations. We support an extensive ecosystem of unique components accessible via APIs and complemented by a growing number of strategic integrations that help our customers and partners modernize their contact centers at their pace and with the security, flexibility, and customization they require. To learn more, visit www.alvaria.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513715151/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines to Present at Upcoming Investor Conferences28.10.2025 11:01:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 9:30 am EST; and Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:00 pm GMT/11:00 am EST Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through

Allianz Reports Safety Gains From Automated Mobility and Urges EU-Wide “Driving License” for Autonomous Vehicles28.10.2025 10:05:00 CET | Press release

Strategic priorities for safe autonomous mobility: Allianz calls for EU-wide uniform testing standards for the approval of autonomous vehicles, free access to accident- and safety-related in-vehicle data, and a joint European database for critical traffic situations.Predicted Safety Improvements: Allianz forecasts a 20 percent reduction in traffic accidents by 2035, increasing to over 50 percent by 2060, thanks to autonomous technology.Allianz claims analysis confirms that currently available autonomous braking assistance systems reduce the frequency of specific accidents by 66 percent.Consumer confidence and concerns: A survey across seven European countries reveals that while consumers expect safety improvements, they remain cautious about technological maturity and reliability.Victim protection is essential: Current liability and compulsory insurance models in motor insurance across most EU countries are suitable for autonomous vehicles. The promise of autonomous mobility is not jus

Ares Management and Slate Asset Management to Acquire Polish Real Estate Portfolio Valued at Over €300 Million From Trei Real Estate28.10.2025 09:15:00 CET | Press release

Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, and Slate Asset Management (“Slate”), a global investor and manager focused on essential real estate and infrastructure, today announced that a joint venture between Ares Real Estate funds (“Ares Real Estate”) and Slate has agreed to acquire a portfolio of 36 properties in Poland (the “Portfolio”) from Trei Real Estate, an internationally active developer and asset manager. The Portfolio is valued at over €300 million. The Portfolio comprises 36 recently developed and fully occupied convenience-led retail parks strategically located across major Polish metropolitan areas near large catchment populations. The assets are inflation-protected through CPI-linked lease agreements underpinned by tenants with strong covenants. Most of the Portfolio’s income is derived from large regional retailers and essential goods providers, including grocers and pharmacies. “This transaction underlines our c

SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia28.10.2025 09:00:00 CET | Press release

Green certification is the top tier of the globally recognized My Green Lab program for laboratory sustainability excellence SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green Lab certifications, including two at the program’s highest level, Green. The remaining two labs earned Gold certification, reflecting advanced sustainability performance and progression toward full Green maturity. The certified facilities are Small Molecule Europe (Swords, Ireland) and Small Molecule Asia (Daejeon, South Korea), and the certifications cover the areas of Quality Control, Process Research & Development, and Analytical Research & Development. My Green Lab certification is widely regarded as the global standard for laboratory sustainability, recognized by the United Nations Race to Zero campaign for its rigor in advancing credible decarbonization. Green ce

Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing28.10.2025 07:00:00 CET | Press release

Milestone expands India’s role in global biologics manufacturing; collaboration with Cipla underscores commitment to quality and reliability Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. It demonstrates the company’s ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards. “Achieving FDA clearance for commercial manufacturing from our Bengaluru sit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye